Next Article in Journal
Biofunctional Constituents from Liriodendron tulipifera with Antioxidants and Anti-Melanogenic Properties
Next Article in Special Issue
Differential mRNA Expression Levels of Human Histone-Modifying Enzymes in Normal Karyotype B Cell Pediatric Acute Lymphoblastic Leukemia
Previous Article in Journal
Crystal Structure of Dimeric Flavodoxin from Desulfovibrio gigas Suggests a Potential Binding Region for the Electron-Transferring Partner
Previous Article in Special Issue
Inhibitor of Apoptosis Protein-Like Protein-2 as a Novel Serological Biomarker for Breast Cancer
Int. J. Mol. Sci. 2013, 14(1), 1684-1697; doi:10.3390/ijms14011684

Expression of Partitioning Defective 3 (Par-3) for Predicting Extrahepatic Metastasis and Survival with Hepatocellular Carcinoma

1 Department of Pathology and Laboratory Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan 2 Institute of Cellular and System Medicine, National Health Research Institutes, Zhunan 350, Taiwan 3 Department of Internal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan 4 Department of Surgery, National Taiwan University Hospital, Taipei 100, Taiwan 5 Graduate Institute of Basic Medical Science, China Medical University, Taichung 404, Taiwan These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 23 November 2012 / Revised: 4 January 2013 / Accepted: 6 January 2013 / Published: 15 January 2013
(This article belongs to the Special Issue Advances in Cancer Diagnosis)
View Full-Text   |   Download PDF [1781 KB, uploaded 19 June 2014]   |   Browse Figures


Partitioning defective 3 (Par-3), a crucial component of partitioning-defective complex proteins, controls cell polarity and contributes to cell migration and cancer cell epithelial-to-mesenchymal transition. However, the clinical relevance of Par-3 in tumor progression and metastasis has not been well elucidated. In this study, we investigated the impact and association of Par-3 expression and clinical outcomes with hepatocellular carcinoma (HCC). We first confirmed that Par-3 was abundantly expressed in HCC cell lines by Western blot analysis. We used immunohistochemistry to analyze the association of Par-3 expression and clinicopathological characteristics in primary and subsequent metastatic tumors of patients with HCC. Par-3 was overexpressed in 47 of 111 (42.3%) primary tumors. Increased expression of Par-3 in primary tumors predicted an increased five-year cumulative incidence of extrahepatic metastasis. In addition, multivariate analysis revealed that Par-3 overexpression was an independent risk factor of extrahepatic metastasis. Increased Par-3 expression in primary tumors was associated with poor five-year overall survival rates and was an independent prognostic factor on Cox regression analysis. In conclusion, we show for the first time that increased Par-3 expression is associated with distant metastasis and poor survival rates in patients with HCC. Par-3 may be a novel prognostic biomarker and therapeutic target for HCC.
Keywords: hepatocellular carcinoma; metastasis; Par-3; survival hepatocellular carcinoma; metastasis; Par-3; survival
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Jan, Y.-J.; Ko, B.-S.; Liu, T.-A.; Wu, Y.-M.; Liang, S.-M.; Chen, S.-C.; Wang, J.; Liou, J.-Y. Expression of Partitioning Defective 3 (Par-3) for Predicting Extrahepatic Metastasis and Survival with Hepatocellular Carcinoma. Int. J. Mol. Sci. 2013, 14, 1684-1697.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert